Search
European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016
On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).
Read moreThe Clot Thickens
Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).
Read moreGenome sequencing of thousands of patients with rare blood disorders
Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.
Read moreEvaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…
PRESS RELEASE: The future of research in hematology is here
“For the first time, hematologists in Europe came together to develop a roadmap to guide hematology research in Europe” says Professor Andreas Engert, chair of the EHA Research Roadmap Task Force, “Hematology in Europe has achieved a lot, but the discipline must focus and…
Read moreA European Reference Network for Rare Hematological Diseases
You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.
Read moreIMI2 Call for Research Proposals
The indicative budget for this topic is 40 million Euro, half of which by way of an in kind contribution from Industry Consortium EFPIA (European Federation of Pharmaceutical Industries and Associations) companies.
Read moreA new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.
Read moreAdding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read moreNovel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing
Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- »